Pramlintide vs Tirzepatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Pramlintide
Pramlintide (Symlin) is a synthetic analog of amylin, FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. It helps control post-meal blood sugar spikes and promotes modest weight loss.
Full details →Tirzepatide
Tirzepatide is the first dual GIP/GLP-1 receptor agonist — a 39-amino acid synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). In clinical trials, tirzepatide demonstrated greater weight loss than semaglutide, with up to 22.5% body weight reduction at the highest dose.
Full details →Side-by-Side Comparison
| Aspect | Pramlintide | Tirzepatide |
|---|---|---|
| Dose Range | 15 mcg–120 mcg | 2.5 mg–15 mg |
| Frequency | 3x daily | Less than daily |
| Cycle Length | 12–52 weeks | 16–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Mimics amylin's effects: slows gastric emptying, suppresses glucagon secretion after meals, and promotes satiety through central mechanisms. Complements insulin therapy. | Tirzepatide is based on the GIP peptide sequence with modifications enabling dual agonism at both GIP and GLP-1 receptors. GIP receptor activation enhances the effects of GLP-1 signaling: (1) potentiated insulin secretion beyond GLP-1 alone, (2) improved beta-cell function, (3) enhanced adipose tissue signaling that may improve fat metabolism, (4) potential protection against GLP-1-induced nausea via GIP receptor activity. The peptide has a C20 fatty diacid moiety enabling albumin binding and once-weekly dosing (half-life ~5 days). The dual mechanism explains the superior weight loss and glycemic outcomes compared to selective GLP-1 agonists. |
| Typical Dosage | Type 1: Start 15mcg before meals, titrate to 30-60mcg. Type 2: Start 60mcg, may increase to 120mcg. Always with meal containing 30+ grams carbs or 250+ calories. | For weight management (Zepbound): start at 2.5 mg weekly for 4 weeks. Escalate to 5 mg for 4 weeks, then 7.5 mg for 4 weeks, then 10 mg. May increase to 12.5 mg, then maximum 15 mg weekly. For type 2 diabetes (Mounjaro): same escalation schedule, maintenance at 5 mg, 10 mg, or 15 mg based on glycemic response. |
| Administration | Subcutaneous injection immediately before major meals. Must reduce mealtime insulin by 50% when starting to prevent hypoglycemia. Never mix with insulin. | Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate injection sites. Pre-filled single-dose pen — no reconstitution needed. Store refrigerated before first use; may be stored at room temperature (up to 86°F) for up to 21 days. Administer on the same day each week; may change the day if the last dose was given 3+ days prior. |
| Side Effects | Nausea (very common initially), headache, anorexia, vomiting, and abdominal pain. GI effects typically improve over time. | Very common (>10%): nausea (up to 33%), diarrhea (up to 25%), decreased appetite, vomiting, constipation, dyspepsia, abdominal pain. Generally milder GI side effects than semaglutide, potentially due to GIP receptor co-activation. Common (1-10%): injection site reactions, fatigue, hypersensitivity reactions, GERD, hair loss, eructation. |
| Best For |
Key Differences
Unique to Pramlintide:
Unique to Tirzepatide:
Key Studies
Pramlintide
- Chronic pramlintide decreases feeding via a reduction in meal size in male rats.
Peptides, 2024
- Pramlintide an Adjunct to Insulin Therapy: Challenges and Recent Progress in Delivery.
The Journal of pharmacology and experimental therapeutics, 2024
- Pramlintide for post-bariatric hypoglycaemia.
Diabetes, obesity & metabolism, 2022
Tirzepatide
- Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.
Cell metabolism, 2025
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
The New England journal of medicine, 2025
- Tirzepatide for Obesity Treatment and Diabetes Prevention.
The New England journal of medicine, 2025
Ready to Learn More?
Looking for trusted sources?